采用不同 BCMA 靶向疗法对复发/难治性多发性骨髓瘤进行序贯治疗。
Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies.
机构信息
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Memorial Sloan Kettering Cancer Center, New York, NY.
出版信息
Blood Adv. 2019 Aug 27;3(16):2487-2490. doi: 10.1182/bloodadvances.2019000466.
Abstract
Myeloma patients progressing on BCMA-targeted therapy can maintain BCMA expression and still respond to different BCMA-targeted therapy. These observations suggest this patient population could be included in ongoing BCMA-targeted therapy trials.
摘要
多发性骨髓瘤患者在接受 BCMA 靶向治疗后进展，可以保持 BCMA 表达，并且仍然对不同的 BCMA 靶向治疗有反应。这些观察结果表明，这类患者人群可以纳入正在进行的 BCMA 靶向治疗试验中。
相似文献
1
Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies.采用不同 BCMA 靶向疗法对复发/难治性多发性骨髓瘤进行序贯治疗。
Blood Adv. 2019 Aug 27;3(16):2487-2490. doi: 10.1182/bloodadvances.2019000466.
2
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.B 细胞成熟抗原（BCMA）在多发性骨髓瘤中的作用：靶向治疗的原理和当前的治疗方法。
Leukemia. 2020 Apr;34(4):985-1005. doi: 10.1038/s41375-020-0734-z. Epub 2020 Feb 13.
3
Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma.抗BCMA抗体药物偶联物AMG 224用于复发/难治性多发性骨髓瘤患者的1期研究。
Leukemia. 2021 Jan;35(1):255-258. doi: 10.1038/s41375-020-0834-9. Epub 2020 Apr 21.
4
The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.用于治疗难治性/复发性多发性骨髓瘤的分泌白细胞介素-7和CCL19的靶向B细胞成熟抗原的第四代嵌合抗原受体T细胞
Front Immunol. 2021 Mar 5;12:609421. doi: 10.3389/fimmu.2021.609421. eCollection 2021.
5
BCMA-targeting approaches for treatment of multiple myeloma.BCMA 靶向治疗多发性骨髓瘤。
Panminerva Med. 2021 Mar;63(1):28-36. doi: 10.23736/S0031-0808.20.04121-X. Epub 2020 Sep 21.
6
SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents.SOHO 最新进展及待解决问题：多发性骨髓瘤的 T 细胞靶向免疫治疗：嵌合抗原受体修饰 T 细胞和双特异性 T 细胞衔接剂。
Clin Lymphoma Myeloma Leuk. 2019 Sep;19(9):537-544. doi: 10.1016/j.clml.2019.08.002. Epub 2019 Aug 7.
7
Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma.伊达基奥仑赛（ide-cel）嵌合抗原受体 T 细胞疗法治疗复发/难治性多发性骨髓瘤。
Future Oncol. 2022 Jan;18(3):277-289. doi: 10.2217/fon-2021-1090. Epub 2021 Dec 2.
8
Multiple Myeloma: The CAR T-cell Therapy Landscape.多发性骨髓瘤：CAR-T 细胞治疗全景。
Cancer Discov. 2020 Feb;10(2):OF6. doi: 10.1158/2159-8290.CD-ND2019-015. Epub 2020 Jan 8.
9
Targeting BCMA in Multiple Myeloma.多发性骨髓瘤中的 BCMA 靶向治疗。
Curr Hematol Malig Rep. 2021 Oct;16(5):367-383. doi: 10.1007/s11899-021-00639-z. Epub 2021 Aug 25.
10
Antibody-Based Treatment Approaches in Multiple Myeloma.基于抗体的多发性骨髓瘤治疗方法。
Curr Hematol Malig Rep. 2021 Apr;16(2):183-191. doi: 10.1007/s11899-021-00624-6. Epub 2021 Mar 17.
引用本文的文献
1
CAR T-cell therapy to treat multiple myeloma: current state and future directions.嵌合抗原受体T细胞疗法治疗多发性骨髓瘤：现状与未来方向
Cancer Metastasis Rev. 2024 Dec 3;44(1):14. doi: 10.1007/s10555-024-10219-1.
2
T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma: Optimal Dosing Schedule and Duration of Treatment.T 细胞重定向双特异性抗体在多发性骨髓瘤中的应用：最佳给药方案和治疗持续时间。
Blood Cancer Discov. 2024 Nov 1;5(6):388-399. doi: 10.1158/2643-3230.BCD-24-0124.
3
Challenges and strategies associated with CAR-T cell therapy in blood malignancies.血液恶性肿瘤中与嵌合抗原受体T细胞（CAR-T）疗法相关的挑战与策略。
Exp Hematol Oncol. 2024 Feb 24;13(1):22. doi: 10.1186/s40164-024-00490-x.
4
Options at the time of relapse after anti-BCMA therapy.抗 BCMA 治疗后复发时的选择。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):450-458. doi: 10.1182/hematology.2023000445.
5
Beyond BCMA, why GPRC5D could be the right way: treatment strategies with immunotherapy at relapse after anti-BCMA agents.除了 BCMA，为什么 GPRC5D 是正确的选择：抗 BCMA 药物治疗后复发时的免疫治疗策略。
Cancer Immunol Immunother. 2023 Dec;72(12):3931-3937. doi: 10.1007/s00262-023-03559-4. Epub 2023 Nov 4.
6
Management of Relapsed-Refractory Multiple Myeloma in the Era of Advanced Therapies: Evidence-Based Recommendations for Routine Clinical Practice.先进疗法时代复发难治性多发性骨髓瘤的管理：基于证据的常规临床实践建议
Cancers (Basel). 2023 Apr 5;15(7):2160. doi: 10.3390/cancers15072160.
7
Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance.创新的抗 CD38 和抗 BCMA 靶向疗法在多发性骨髓瘤中的作用机制和耐药性。
Int J Mol Sci. 2022 Dec 30;24(1):645. doi: 10.3390/ijms24010645.
8
Efficacy and safety of belantamab-mafodotin in triple-refractory multiple myeloma patients: A multicentric real-life experience.贝兰他单抗马福多汀在三重难治性多发性骨髓瘤患者中的疗效与安全性：一项多中心真实世界经验。
Front Oncol. 2022 Nov 15;12:1026251. doi: 10.3389/fonc.2022.1026251. eCollection 2022.
9
BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice.BCMA 缺失在多发性骨髓瘤新型免疫治疗时代：从生物学到临床实践。
Haematologica. 2023 Apr 1;108(4):958-968. doi: 10.3324/haematol.2020.266841.
10
Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial.新型国产抗 BCMA CAR T 细胞的研发与生产用于治疗复发/难治性多发性骨髓瘤：I 期临床试验结果。
Haematologica. 2023 Jul 1;108(7):1827-1839. doi: 10.3324/haematol.2022.281628.
本文引用的文献
1
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma.抗 BCMA CAR T 细胞疗法 bb2121 治疗复发/难治性多发性骨髓瘤。
N Engl J Med. 2019 May 2;380(18):1726-1737. doi: 10.1056/NEJMoa1817226.
2
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.B 细胞成熟抗原特异性嵌合抗原受体 T 细胞在多发性骨髓瘤中具有临床活性。
J Clin Invest. 2019 Mar 21;129(6):2210-2221. doi: 10.1172/JCI126397.
3
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.以复发或难治性多发性骨髓瘤中的 B 细胞成熟抗原为靶点的 GSK2857916 抗体药物偶联物（BMA117159）：一项剂量递增和扩展的 1 期试验。
Lancet Oncol. 2018 Dec;19(12):1641-1653. doi: 10.1016/S1470-2045(18)30576-X. Epub 2018 Nov 12.
4
Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma.骨髓瘤新型嵌合抗原受体T细胞疗法的靶点——B细胞成熟抗原的定量分析
Leuk Res. 2018 Aug;71:106-111. doi: 10.1016/j.leukres.2018.07.015. Epub 2018 Jul 18.
5
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.经基因修饰表达抗 B 细胞成熟抗原嵌合抗原受体的 T 细胞可引起预后不良的复发性多发性骨髓瘤缓解。
J Clin Oncol. 2018 Aug 1;36(22):2267-2280. doi: 10.1200/JCO.2018.77.8084. Epub 2018 May 29.
6
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.慢性淋巴细胞白血病中 CD19 嵌合抗原受体 (CAR) T 细胞治疗应答和耐药的决定因素。
Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30.
7
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.BCMA-T 细胞双特异性抗体 EM801 用于多发性骨髓瘤治疗的靶表达、生成、临床前活性和药代动力学。
Cancer Cell. 2017 Mar 13;31(3):396-410. doi: 10.1016/j.ccell.2017.02.002. Epub 2017 Mar 2.
8
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.具有细胞内源性程序性死亡蛋白1（PD-1）检查点阻断功能的人嵌合抗原受体（CAR）T细胞可抵抗肿瘤介导的抑制作用。
J Clin Invest. 2016 Aug 1;126(8):3130-44. doi: 10.1172/JCI83092. Epub 2016 Jul 25.
9
Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.评估B细胞成熟抗原作为抗体药物偶联物介导的多发性骨髓瘤细胞毒性靶点的作用
Br J Haematol. 2016 Sep;174(6):911-22. doi: 10.1111/bjh.14145. Epub 2016 Jun 17.
10
Chimeric antigen receptor T cells for sustained remissions in leukemia.用于白血病持续缓解的嵌合抗原受体T细胞。
N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222.
Zotero 插件